nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP19A1—Betamethasone—psoriasis	0.0449	0.0613	CbGbCtD
Methadone—CYP2C8—Tazarotene—psoriasis	0.0442	0.0603	CbGbCtD
Methadone—CYP3A5—Beclomethasone—psoriasis	0.0427	0.0583	CbGbCtD
Methadone—CYP1A2—Clobetasol propionate—psoriasis	0.0419	0.0573	CbGbCtD
Methadone—CYP19A1—Dexamethasone—psoriasis	0.0261	0.0357	CbGbCtD
Methadone—CYP2B6—Cholecalciferol—psoriasis	0.0249	0.034	CbGbCtD
Methadone—CYP1A2—Methoxsalen—psoriasis	0.022	0.0301	CbGbCtD
Methadone—CYP2D6—Hydroxyurea—psoriasis	0.0198	0.0271	CbGbCtD
Methadone—CYP2C8—Cholecalciferol—psoriasis	0.0188	0.0258	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0182	0.0248	CbGbCtD
Methadone—CYP3A7—Hydrocortisone—psoriasis	0.0182	0.0248	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0172	0.0235	CbGbCtD
Methadone—CYP3A7—Cyclosporine—psoriasis	0.0172	0.0235	CbGbCtD
Methadone—CYP3A5—Mycophenolate mofetil—psoriasis	0.017	0.0232	CbGbCtD
Methadone—CYP2C8—Mycophenolate mofetil—psoriasis	0.0163	0.0223	CbGbCtD
Methadone—CYP2C19—Cholecalciferol—psoriasis	0.0158	0.0216	CbGbCtD
Methadone—CYP3A4—Calcitriol—psoriasis	0.0148	0.0203	CbGbCtD
Methadone—CYP3A5—Hydrocortisone—psoriasis	0.0136	0.0186	CbGbCtD
Methadone—CYP2C9—Cholecalciferol—psoriasis	0.0131	0.018	CbGbCtD
Methadone—CYP2C8—Hydrocortisone—psoriasis	0.0131	0.0179	CbGbCtD
Methadone—CYP3A5—Cyclosporine—psoriasis	0.0129	0.0176	CbGbCtD
Methadone—CYP2C8—Cyclosporine—psoriasis	0.0124	0.0169	CbGbCtD
Methadone—CYP2D6—Cholecalciferol—psoriasis	0.012	0.0164	CbGbCtD
Methadone—CYP3A4—Methoxsalen—psoriasis	0.0115	0.0158	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0113	0.0155	CbGbCtD
Methadone—CYP3A7—Dexamethasone—psoriasis	0.0113	0.0155	CbGbCtD
Methadone—ABCB1—Mycophenolate mofetil—psoriasis	0.0111	0.0151	CbGbCtD
Methadone—CYP2C19—Prednisone—psoriasis	0.011	0.015	CbGbCtD
Methadone—CYP2B6—Dexamethasone—psoriasis	0.0108	0.0147	CbGbCtD
Methadone—CYP2C19—Cyclosporine—psoriasis	0.0104	0.0142	CbGbCtD
Methadone—ABCB1—Betamethasone—psoriasis	0.00949	0.013	CbGbCtD
Methadone—ABCB1—Prednisolone—psoriasis	0.00936	0.0128	CbGbCtD
Methadone—ABCB1—Hydrocortisone—psoriasis	0.00888	0.0121	CbGbCtD
Methadone—ABCB1—Prednisone—psoriasis	0.00884	0.0121	CbGbCtD
Methadone—CYP2C9—Cyclosporine—psoriasis	0.00864	0.0118	CbGbCtD
Methadone—CYP3A5—Dexamethasone—psoriasis	0.00848	0.0116	CbGbCtD
Methadone—ABCB1—Cyclosporine—psoriasis	0.00838	0.0115	CbGbCtD
Methadone—CYP2C8—Dexamethasone—psoriasis	0.00816	0.0111	CbGbCtD
Methadone—CYP2D6—Cyclosporine—psoriasis	0.0079	0.0108	CbGbCtD
Methadone—CYP3A4—Cholecalciferol—psoriasis	0.00764	0.0104	CbGbCtD
Methadone—CYP2C19—Dexamethasone—psoriasis	0.00684	0.00935	CbGbCtD
Methadone—CYP3A4—Triamcinolone—psoriasis	0.00663	0.00906	CbGbCtD
Methadone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00663	0.00906	CbGbCtD
Methadone—CYP2C9—Dexamethasone—psoriasis	0.00569	0.00777	CbGbCtD
Methadone—CYP3A4—Betamethasone—psoriasis	0.00569	0.00777	CbGbCtD
Methadone—CYP3A4—Prednisolone—psoriasis	0.00561	0.00767	CbGbCtD
Methadone—ABCB1—Dexamethasone—psoriasis	0.00552	0.00754	CbGbCtD
Methadone—CYP3A4—Hydrocortisone—psoriasis	0.00532	0.00727	CbGbCtD
Methadone—CYP3A4—Prednisone—psoriasis	0.0053	0.00724	CbGbCtD
Methadone—CYP2D6—Dexamethasone—psoriasis	0.0052	0.00711	CbGbCtD
Methadone—CYP3A4—Cyclosporine—psoriasis	0.00502	0.00686	CbGbCtD
Methadone—ABCB1—Methotrexate—psoriasis	0.00444	0.00606	CbGbCtD
Methadone—CYP3A4—Dexamethasone—psoriasis	0.00331	0.00452	CbGbCtD
Methadone—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000149	0.00262	CbGpPWpGaD
Methadone—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000148	0.000701	CcSEcCtD
Methadone—Vomiting—Hydroxyurea—psoriasis	0.000147	0.000698	CcSEcCtD
Methadone—Rash—Hydroxyurea—psoriasis	0.000146	0.000692	CcSEcCtD
Methadone—Erythema—Betamethasone—psoriasis	0.000146	0.000692	CcSEcCtD
Methadone—Erythema—Dexamethasone—psoriasis	0.000146	0.000692	CcSEcCtD
Methadone—Anorexia—Mycophenolate mofetil—psoriasis	0.000146	0.000691	CcSEcCtD
Methadone—Dermatitis—Hydroxyurea—psoriasis	0.000146	0.000691	CcSEcCtD
Methadone—Hallucination—Prednisone—psoriasis	0.000145	0.000688	CcSEcCtD
Methadone—Headache—Hydroxyurea—psoriasis	0.000145	0.000687	CcSEcCtD
Methadone—Anxiety—Hydrocortisone—psoriasis	0.000145	0.000687	CcSEcCtD
Methadone—Vertigo—Triamcinolone—psoriasis	0.000145	0.000685	CcSEcCtD
Methadone—Syncope—Triamcinolone—psoriasis	0.000144	0.000684	CcSEcCtD
Methadone—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	0.000143	0.00251	CbGpPWpGaD
Methadone—Hypotension—Mycophenolate mofetil—psoriasis	0.000143	0.000678	CcSEcCtD
Methadone—Oedema—Prednisolone—psoriasis	0.000143	0.000676	CcSEcCtD
Methadone—Anaphylactic shock—Prednisolone—psoriasis	0.000143	0.000676	CcSEcCtD
Methadone—Insomnia—Cyclosporine—psoriasis	0.000142	0.000672	CcSEcCtD
Methadone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000142	0.00248	CbGpPWpGaD
Methadone—Loss of consciousness—Triamcinolone—psoriasis	0.000141	0.00067	CcSEcCtD
Methadone—Shock—Prednisolone—psoriasis	0.000141	0.000666	CcSEcCtD
Methadone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000141	0.00246	CbGpPWpGaD
Methadone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.00014	0.00245	CbGpPWpGaD
Methadone—Somnolence—Cyclosporine—psoriasis	0.00014	0.000661	CcSEcCtD
Methadone—Oedema—Hydrocortisone—psoriasis	0.00014	0.000661	CcSEcCtD
Methadone—Anaphylactic shock—Hydrocortisone—psoriasis	0.00014	0.000661	CcSEcCtD
Methadone—Convulsion—Triamcinolone—psoriasis	0.000139	0.00066	CcSEcCtD
Methadone—Tachycardia—Prednisolone—psoriasis	0.000139	0.00066	CcSEcCtD
Methadone—Asthenia—Mycophenolic acid—psoriasis	0.000139	0.000659	CcSEcCtD
Methadone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000139	0.00243	CbGpPWpGaD
Methadone—Insomnia—Mycophenolate mofetil—psoriasis	0.000139	0.000656	CcSEcCtD
Methadone—Hyperhidrosis—Prednisolone—psoriasis	0.000138	0.000654	CcSEcCtD
Methadone—Nausea—Hydroxyurea—psoriasis	0.000138	0.000652	CcSEcCtD
Methadone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000137	0.00241	CbGpPWpGaD
Methadone—Pruritus—Mycophenolic acid—psoriasis	0.000137	0.00065	CcSEcCtD
Methadone—Shock—Hydrocortisone—psoriasis	0.000137	0.00065	CcSEcCtD
Methadone—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000137	0.00239	CbGpPWpGaD
Methadone—Decreased appetite—Cyclosporine—psoriasis	0.000136	0.000646	CcSEcCtD
Methadone—Tachycardia—Hydrocortisone—psoriasis	0.000136	0.000645	CcSEcCtD
Methadone—Somnolence—Mycophenolate mofetil—psoriasis	0.000136	0.000645	CcSEcCtD
Methadone—Drowsiness—Methotrexate—psoriasis	0.000136	0.000644	CcSEcCtD
Methadone—Flushing—Prednisone—psoriasis	0.000136	0.000642	CcSEcCtD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000135	0.00236	CbGpPWpGaD
Methadone—Hyperhidrosis—Hydrocortisone—psoriasis	0.000135	0.000639	CcSEcCtD
Methadone—Constipation—Cyclosporine—psoriasis	0.000134	0.000636	CcSEcCtD
Methadone—Pain—Cyclosporine—psoriasis	0.000134	0.000636	CcSEcCtD
Methadone—Dry mouth—Triamcinolone—psoriasis	0.000134	0.000635	CcSEcCtD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000134	0.00234	CbGpPWpGaD
Methadone—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000133	0.00063	CcSEcCtD
Methadone—Anorexia—Hydrocortisone—psoriasis	0.000133	0.00063	CcSEcCtD
Methadone—Diarrhoea—Mycophenolic acid—psoriasis	0.000133	0.000629	CcSEcCtD
Methadone—Oedema—Triamcinolone—psoriasis	0.000131	0.000622	CcSEcCtD
Methadone—Anaphylactic shock—Triamcinolone—psoriasis	0.000131	0.000622	CcSEcCtD
Methadone—Vertigo—Betamethasone—psoriasis	0.000131	0.000621	CcSEcCtD
Methadone—Vertigo—Dexamethasone—psoriasis	0.000131	0.000621	CcSEcCtD
Methadone—Syncope—Dexamethasone—psoriasis	0.000131	0.00062	CcSEcCtD
Methadone—Syncope—Betamethasone—psoriasis	0.000131	0.00062	CcSEcCtD
Methadone—Pain—Mycophenolate mofetil—psoriasis	0.000131	0.00062	CcSEcCtD
Methadone—Constipation—Mycophenolate mofetil—psoriasis	0.000131	0.00062	CcSEcCtD
Methadone—Arrhythmia—Prednisone—psoriasis	0.000131	0.000618	CcSEcCtD
Methadone—Sweating—Methotrexate—psoriasis	0.00013	0.000618	CcSEcCtD
Methadone—Hypotension—Hydrocortisone—psoriasis	0.00013	0.000617	CcSEcCtD
Methadone—Feeling abnormal—Cyclosporine—psoriasis	0.000129	0.000613	CcSEcCtD
Methadone—Shock—Triamcinolone—psoriasis	0.000129	0.000612	CcSEcCtD
Methadone—Insomnia—Prednisolone—psoriasis	0.000129	0.000612	CcSEcCtD
Methadone—Gastrointestinal pain—Cyclosporine—psoriasis	0.000128	0.000608	CcSEcCtD
Methadone—Loss of consciousness—Betamethasone—psoriasis	0.000128	0.000608	CcSEcCtD
Methadone—Loss of consciousness—Dexamethasone—psoriasis	0.000128	0.000608	CcSEcCtD
Methadone—Dizziness—Mycophenolic acid—psoriasis	0.000128	0.000608	CcSEcCtD
Methadone—Tachycardia—Triamcinolone—psoriasis	0.000128	0.000607	CcSEcCtD
Methadone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000128	0.00224	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000128	0.00224	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	0.000128	0.00223	CbGpPWpGaD
Methadone—Erythema—Prednisone—psoriasis	0.000127	0.000602	CcSEcCtD
Methadone—ABCB1—Allograft Rejection—IL13—psoriasis	0.000127	0.00223	CbGpPWpGaD
Methadone—Hyperhidrosis—Triamcinolone—psoriasis	0.000127	0.000601	CcSEcCtD
Methadone—Convulsion—Dexamethasone—psoriasis	0.000127	0.000599	CcSEcCtD
Methadone—Convulsion—Betamethasone—psoriasis	0.000127	0.000599	CcSEcCtD
Methadone—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000126	0.000598	CcSEcCtD
Methadone—Insomnia—Hydrocortisone—psoriasis	0.000126	0.000598	CcSEcCtD
Methadone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000125	0.000593	CcSEcCtD
Methadone—Urticaria—Cyclosporine—psoriasis	0.000125	0.000591	CcSEcCtD
Methadone—Abdominal pain—Cyclosporine—psoriasis	0.000124	0.000588	CcSEcCtD
Methadone—Body temperature increased—Cyclosporine—psoriasis	0.000124	0.000588	CcSEcCtD
Methadone—Anxiety—Dexamethasone—psoriasis	0.000124	0.000587	CcSEcCtD
Methadone—Anxiety—Betamethasone—psoriasis	0.000124	0.000587	CcSEcCtD
Methadone—Vomiting—Mycophenolic acid—psoriasis	0.000123	0.000584	CcSEcCtD
Methadone—Rash—Mycophenolic acid—psoriasis	0.000122	0.000579	CcSEcCtD
Methadone—Dermatitis—Mycophenolic acid—psoriasis	0.000122	0.000579	CcSEcCtD
Methadone—Pain—Prednisolone—psoriasis	0.000122	0.000578	CcSEcCtD
Methadone—Urticaria—Mycophenolate mofetil—psoriasis	0.000122	0.000576	CcSEcCtD
Methadone—Headache—Mycophenolic acid—psoriasis	0.000122	0.000576	CcSEcCtD
Methadone—Decreased appetite—Hydrocortisone—psoriasis	0.000121	0.000574	CcSEcCtD
Methadone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000121	0.000573	CcSEcCtD
Methadone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000121	0.000573	CcSEcCtD
Methadone—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.00012	0.0021	CbGpPWpGaD
Methadone—Pain—Hydrocortisone—psoriasis	0.000119	0.000565	CcSEcCtD
Methadone—Oedema—Dexamethasone—psoriasis	0.000119	0.000564	CcSEcCtD
Methadone—Oedema—Betamethasone—psoriasis	0.000119	0.000564	CcSEcCtD
Methadone—Anaphylactic shock—Betamethasone—psoriasis	0.000119	0.000564	CcSEcCtD
Methadone—Anaphylactic shock—Dexamethasone—psoriasis	0.000119	0.000564	CcSEcCtD
Methadone—HTR3A—Transmembrane transport of small molecules—CP—psoriasis	0.000119	0.00208	CbGpPWpGaD
Methadone—Insomnia—Triamcinolone—psoriasis	0.000119	0.000563	CcSEcCtD
Methadone—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000118	0.00207	CbGpPWpGaD
Methadone—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000118	0.00207	CbGpPWpGaD
Methadone—Feeling abnormal—Prednisolone—psoriasis	0.000118	0.000557	CcSEcCtD
Methadone—Visual impairment—Methotrexate—psoriasis	0.000118	0.000557	CcSEcCtD
Methadone—Shock—Betamethasone—psoriasis	0.000117	0.000555	CcSEcCtD
Methadone—Shock—Dexamethasone—psoriasis	0.000117	0.000555	CcSEcCtD
Methadone—OPRD1—GPCR ligand binding—CCL20—psoriasis	0.000117	0.00205	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	0.000117	0.00205	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000117	0.00205	CbGpPWpGaD
Methadone—Agitation—Prednisone—psoriasis	0.000117	0.000553	CcSEcCtD
Methadone—Thrombocytopenia—Betamethasone—psoriasis	0.000117	0.000553	CcSEcCtD
Methadone—Thrombocytopenia—Dexamethasone—psoriasis	0.000117	0.000553	CcSEcCtD
Methadone—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000116	0.00204	CbGpPWpGaD
Methadone—Tachycardia—Betamethasone—psoriasis	0.000116	0.000551	CcSEcCtD
Methadone—Tachycardia—Dexamethasone—psoriasis	0.000116	0.000551	CcSEcCtD
Methadone—OPRD1—Signaling by GPCR—HCAR2—psoriasis	0.000116	0.00203	CbGpPWpGaD
Methadone—Hypersensitivity—Cyclosporine—psoriasis	0.000116	0.000548	CcSEcCtD
Methadone—Nausea—Mycophenolic acid—psoriasis	0.000115	0.000546	CcSEcCtD
Methadone—Hyperhidrosis—Betamethasone—psoriasis	0.000115	0.000546	CcSEcCtD
Methadone—Hyperhidrosis—Dexamethasone—psoriasis	0.000115	0.000546	CcSEcCtD
Methadone—Feeling abnormal—Hydrocortisone—psoriasis	0.000115	0.000544	CcSEcCtD
Methadone—Vertigo—Prednisone—psoriasis	0.000114	0.000541	CcSEcCtD
Methadone—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000114	0.00054	CcSEcCtD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000114	0.002	CbGpPWpGaD
Methadone—Syncope—Prednisone—psoriasis	0.000114	0.00054	CcSEcCtD
Methadone—Anorexia—Dexamethasone—psoriasis	0.000114	0.000538	CcSEcCtD
Methadone—Anorexia—Betamethasone—psoriasis	0.000114	0.000538	CcSEcCtD
Methadone—HTR3A—Transmembrane transport of small molecules—CARM1—psoriasis	0.000114	0.00199	CbGpPWpGaD
Methadone—Urticaria—Prednisolone—psoriasis	0.000114	0.000537	CcSEcCtD
Methadone—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000113	0.000534	CcSEcCtD
Methadone—Asthenia—Cyclosporine—psoriasis	0.000113	0.000533	CcSEcCtD
Methadone—Pain—Triamcinolone—psoriasis	0.000112	0.000532	CcSEcCtD
Methadone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000112	0.00196	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	0.000112	0.00196	CbGpPWpGaD
Methadone—Loss of consciousness—Prednisone—psoriasis	0.000112	0.000529	CcSEcCtD
Methadone—Hypotension—Betamethasone—psoriasis	0.000111	0.000527	CcSEcCtD
Methadone—Hypotension—Dexamethasone—psoriasis	0.000111	0.000527	CcSEcCtD
Methadone—Pruritus—Cyclosporine—psoriasis	0.000111	0.000526	CcSEcCtD
Methadone—Urticaria—Hydrocortisone—psoriasis	0.000111	0.000525	CcSEcCtD
Methadone—Body temperature increased—Hydrocortisone—psoriasis	0.00011	0.000522	CcSEcCtD
Methadone—Abdominal pain—Hydrocortisone—psoriasis	0.00011	0.000522	CcSEcCtD
Methadone—Convulsion—Prednisone—psoriasis	0.00011	0.000522	CcSEcCtD
Methadone—Asthenia—Mycophenolate mofetil—psoriasis	0.00011	0.00052	CcSEcCtD
Methadone—Chills—Methotrexate—psoriasis	0.00011	0.000519	CcSEcCtD
Methadone—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000109	0.00191	CbGpPWpGaD
Methadone—Pruritus—Mycophenolate mofetil—psoriasis	0.000108	0.000513	CcSEcCtD
Methadone—Feeling abnormal—Triamcinolone—psoriasis	0.000108	0.000513	CcSEcCtD
Methadone—Anxiety—Prednisone—psoriasis	0.000108	0.000511	CcSEcCtD
Methadone—Insomnia—Betamethasone—psoriasis	0.000108	0.000511	CcSEcCtD
Methadone—Insomnia—Dexamethasone—psoriasis	0.000108	0.000511	CcSEcCtD
Methadone—Diarrhoea—Cyclosporine—psoriasis	0.000107	0.000509	CcSEcCtD
Methadone—HTR3A—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000107	0.00187	CbGpPWpGaD
Methadone—Erythema—Methotrexate—psoriasis	0.000106	0.000503	CcSEcCtD
Methadone—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000106	0.00186	CbGpPWpGaD
Methadone—Hypersensitivity—Prednisolone—psoriasis	0.000105	0.000498	CcSEcCtD
Methadone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000105	0.000496	CcSEcCtD
Methadone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000105	0.00183	CbGpPWpGaD
Methadone—Urticaria—Triamcinolone—psoriasis	0.000104	0.000494	CcSEcCtD
Methadone—Body temperature increased—Triamcinolone—psoriasis	0.000104	0.000492	CcSEcCtD
Methadone—Dizziness—Cyclosporine—psoriasis	0.000104	0.000492	CcSEcCtD
Methadone—Anaphylactic shock—Prednisone—psoriasis	0.000104	0.000492	CcSEcCtD
Methadone—Oedema—Prednisone—psoriasis	0.000104	0.000492	CcSEcCtD
Methadone—Decreased appetite—Dexamethasone—psoriasis	0.000104	0.000491	CcSEcCtD
Methadone—Decreased appetite—Betamethasone—psoriasis	0.000104	0.000491	CcSEcCtD
Methadone—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000104	0.00181	CbGpPWpGaD
Methadone—Hypersensitivity—Hydrocortisone—psoriasis	0.000103	0.000487	CcSEcCtD
Methadone—OPRK1—GPCR ligand binding—CCL20—psoriasis	0.000103	0.0018	CbGpPWpGaD
Methadone—Shock—Prednisone—psoriasis	0.000102	0.000484	CcSEcCtD
Methadone—Pain—Betamethasone—psoriasis	0.000102	0.000483	CcSEcCtD
Methadone—Pain—Dexamethasone—psoriasis	0.000102	0.000483	CcSEcCtD
Methadone—OPRK1—Signaling by GPCR—HCAR2—psoriasis	0.000102	0.00178	CbGpPWpGaD
Methadone—Tachycardia—Prednisone—psoriasis	0.000101	0.00048	CcSEcCtD
Methadone—Dizziness—Mycophenolate mofetil—psoriasis	0.000101	0.00048	CcSEcCtD
Methadone—Hyperhidrosis—Prednisone—psoriasis	0.0001	0.000475	CcSEcCtD
Methadone—Asthenia—Hydrocortisone—psoriasis	0.0001	0.000474	CcSEcCtD
Methadone—Vomiting—Cyclosporine—psoriasis	9.98e-05	0.000473	CcSEcCtD
Methadone—HTR3A—SIDS Susceptibility Pathways—JUN—psoriasis	9.93e-05	0.00174	CbGpPWpGaD
Methadone—Rash—Cyclosporine—psoriasis	9.9e-05	0.000469	CcSEcCtD
Methadone—Anorexia—Prednisone—psoriasis	9.9e-05	0.000469	CcSEcCtD
Methadone—Dermatitis—Cyclosporine—psoriasis	9.89e-05	0.000468	CcSEcCtD
Methadone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.89e-05	0.00173	CbGpPWpGaD
Methadone—Pruritus—Hydrocortisone—psoriasis	9.87e-05	0.000467	CcSEcCtD
Methadone—Headache—Cyclosporine—psoriasis	9.84e-05	0.000466	CcSEcCtD
Methadone—Feeling abnormal—Betamethasone—psoriasis	9.82e-05	0.000465	CcSEcCtD
Methadone—Feeling abnormal—Dexamethasone—psoriasis	9.82e-05	0.000465	CcSEcCtD
Methadone—Gastrointestinal pain—Betamethasone—psoriasis	9.75e-05	0.000462	CcSEcCtD
Methadone—Gastrointestinal pain—Dexamethasone—psoriasis	9.75e-05	0.000462	CcSEcCtD
Methadone—Vomiting—Mycophenolate mofetil—psoriasis	9.74e-05	0.000461	CcSEcCtD
Methadone—Hypersensitivity—Triamcinolone—psoriasis	9.68e-05	0.000458	CcSEcCtD
Methadone—Rash—Mycophenolate mofetil—psoriasis	9.66e-05	0.000457	CcSEcCtD
Methadone—Dermatitis—Mycophenolate mofetil—psoriasis	9.65e-05	0.000457	CcSEcCtD
Methadone—Headache—Mycophenolate mofetil—psoriasis	9.6e-05	0.000454	CcSEcCtD
Methadone—HTR3A—SIDS Susceptibility Pathways—NFKB1—psoriasis	9.55e-05	0.00167	CbGpPWpGaD
Methadone—Vertigo—Methotrexate—psoriasis	9.55e-05	0.000452	CcSEcCtD
Methadone—Diarrhoea—Hydrocortisone—psoriasis	9.55e-05	0.000452	CcSEcCtD
Methadone—Urticaria—Betamethasone—psoriasis	9.47e-05	0.000448	CcSEcCtD
Methadone—Urticaria—Dexamethasone—psoriasis	9.47e-05	0.000448	CcSEcCtD
Methadone—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	9.45e-05	0.00166	CbGpPWpGaD
Methadone—Dizziness—Prednisolone—psoriasis	9.45e-05	0.000447	CcSEcCtD
Methadone—Asthenia—Triamcinolone—psoriasis	9.43e-05	0.000446	CcSEcCtD
Methadone—Abdominal pain—Dexamethasone—psoriasis	9.42e-05	0.000446	CcSEcCtD
Methadone—Abdominal pain—Betamethasone—psoriasis	9.42e-05	0.000446	CcSEcCtD
Methadone—Body temperature increased—Betamethasone—psoriasis	9.42e-05	0.000446	CcSEcCtD
Methadone—Body temperature increased—Dexamethasone—psoriasis	9.42e-05	0.000446	CcSEcCtD
Methadone—Insomnia—Prednisone—psoriasis	9.39e-05	0.000445	CcSEcCtD
Methadone—Nausea—Cyclosporine—psoriasis	9.33e-05	0.000442	CcSEcCtD
Methadone—Pruritus—Triamcinolone—psoriasis	9.3e-05	0.00044	CcSEcCtD
Methadone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.27e-05	0.00162	CbGpPWpGaD
Methadone—Dizziness—Hydrocortisone—psoriasis	9.23e-05	0.000437	CcSEcCtD
Methadone—Convulsion—Methotrexate—psoriasis	9.21e-05	0.000436	CcSEcCtD
Methadone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.14e-05	0.0016	CbGpPWpGaD
Methadone—Nausea—Mycophenolate mofetil—psoriasis	9.1e-05	0.000431	CcSEcCtD
Methadone—Decreased appetite—Prednisone—psoriasis	9.03e-05	0.000427	CcSEcCtD
Methadone—Rash—Prednisolone—psoriasis	9.01e-05	0.000427	CcSEcCtD
Methadone—Dermatitis—Prednisolone—psoriasis	9e-05	0.000426	CcSEcCtD
Methadone—Headache—Prednisolone—psoriasis	8.95e-05	0.000424	CcSEcCtD
Methadone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.93e-05	0.00156	CbGpPWpGaD
Methadone—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	8.89e-05	0.00156	CbGpPWpGaD
Methadone—Constipation—Prednisone—psoriasis	8.88e-05	0.00042	CcSEcCtD
Methadone—Vomiting—Hydrocortisone—psoriasis	8.87e-05	0.00042	CcSEcCtD
Methadone—Rash—Hydrocortisone—psoriasis	8.8e-05	0.000417	CcSEcCtD
Methadone—Dermatitis—Hydrocortisone—psoriasis	8.79e-05	0.000416	CcSEcCtD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.79e-05	0.00154	CbGpPWpGaD
Methadone—Confusional state—Methotrexate—psoriasis	8.75e-05	0.000414	CcSEcCtD
Methadone—Headache—Hydrocortisone—psoriasis	8.74e-05	0.000414	CcSEcCtD
Methadone—Dizziness—Triamcinolone—psoriasis	8.69e-05	0.000411	CcSEcCtD
Methadone—OPRM1—GPCR ligand binding—CCL20—psoriasis	8.69e-05	0.00152	CbGpPWpGaD
Methadone—Anaphylactic shock—Methotrexate—psoriasis	8.68e-05	0.000411	CcSEcCtD
Methadone—OPRM1—TCR Signaling Pathway—CD4—psoriasis	8.67e-05	0.00152	CbGpPWpGaD
Methadone—HTR3A—SIDS Susceptibility Pathways—VEGFA—psoriasis	8.67e-05	0.00152	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—HCAR2—psoriasis	8.58e-05	0.0015	CbGpPWpGaD
Methadone—Feeling abnormal—Prednisone—psoriasis	8.56e-05	0.000405	CcSEcCtD
Methadone—Asthenia—Betamethasone—psoriasis	8.55e-05	0.000405	CcSEcCtD
Methadone—Asthenia—Dexamethasone—psoriasis	8.55e-05	0.000405	CcSEcCtD
Methadone—Thrombocytopenia—Methotrexate—psoriasis	8.5e-05	0.000402	CcSEcCtD
Methadone—Gastrointestinal pain—Prednisone—psoriasis	8.49e-05	0.000402	CcSEcCtD
Methadone—Nausea—Prednisolone—psoriasis	8.49e-05	0.000402	CcSEcCtD
Methadone—Pruritus—Dexamethasone—psoriasis	8.43e-05	0.000399	CcSEcCtD
Methadone—Pruritus—Betamethasone—psoriasis	8.43e-05	0.000399	CcSEcCtD
Methadone—Hyperhidrosis—Methotrexate—psoriasis	8.39e-05	0.000397	CcSEcCtD
Methadone—Vomiting—Triamcinolone—psoriasis	8.35e-05	0.000396	CcSEcCtD
Methadone—CYP2C18—Metabolism—NDUFA5—psoriasis	8.34e-05	0.00146	CbGpPWpGaD
Methadone—Nausea—Hydrocortisone—psoriasis	8.29e-05	0.000392	CcSEcCtD
Methadone—Rash—Triamcinolone—psoriasis	8.28e-05	0.000392	CcSEcCtD
Methadone—Dermatitis—Triamcinolone—psoriasis	8.28e-05	0.000392	CcSEcCtD
Methadone—Anorexia—Methotrexate—psoriasis	8.27e-05	0.000392	CcSEcCtD
Methadone—Urticaria—Prednisone—psoriasis	8.25e-05	0.000391	CcSEcCtD
Methadone—Headache—Triamcinolone—psoriasis	8.23e-05	0.00039	CcSEcCtD
Methadone—Abdominal pain—Prednisone—psoriasis	8.21e-05	0.000389	CcSEcCtD
Methadone—Body temperature increased—Prednisone—psoriasis	8.21e-05	0.000389	CcSEcCtD
Methadone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.17e-05	0.00143	CbGpPWpGaD
Methadone—Diarrhoea—Betamethasone—psoriasis	8.16e-05	0.000386	CcSEcCtD
Methadone—Diarrhoea—Dexamethasone—psoriasis	8.16e-05	0.000386	CcSEcCtD
Methadone—Hypotension—Methotrexate—psoriasis	8.11e-05	0.000384	CcSEcCtD
Methadone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8e-05	0.0014	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL10—psoriasis	7.95e-05	0.00139	CbGpPWpGaD
Methadone—Dizziness—Betamethasone—psoriasis	7.88e-05	0.000373	CcSEcCtD
Methadone—Dizziness—Dexamethasone—psoriasis	7.88e-05	0.000373	CcSEcCtD
Methadone—Insomnia—Methotrexate—psoriasis	7.85e-05	0.000372	CcSEcCtD
Methadone—Nausea—Triamcinolone—psoriasis	7.8e-05	0.00037	CcSEcCtD
Methadone—OPRM1—TCR Signaling Pathway—JUN—psoriasis	7.76e-05	0.00136	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL4—psoriasis	7.74e-05	0.00135	CbGpPWpGaD
Methadone—Somnolence—Methotrexate—psoriasis	7.71e-05	0.000365	CcSEcCtD
Methadone—Hypersensitivity—Prednisone—psoriasis	7.65e-05	0.000362	CcSEcCtD
Methadone—Vomiting—Dexamethasone—psoriasis	7.58e-05	0.000359	CcSEcCtD
Methadone—Vomiting—Betamethasone—psoriasis	7.58e-05	0.000359	CcSEcCtD
Methadone—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.56e-05	0.00132	CbGpPWpGaD
Methadone—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.56e-05	0.00132	CbGpPWpGaD
Methadone—Decreased appetite—Methotrexate—psoriasis	7.54e-05	0.000357	CcSEcCtD
Methadone—Rash—Dexamethasone—psoriasis	7.52e-05	0.000356	CcSEcCtD
Methadone—Rash—Betamethasone—psoriasis	7.52e-05	0.000356	CcSEcCtD
Methadone—Dermatitis—Dexamethasone—psoriasis	7.51e-05	0.000356	CcSEcCtD
Methadone—Dermatitis—Betamethasone—psoriasis	7.51e-05	0.000356	CcSEcCtD
Methadone—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	7.47e-05	0.00131	CbGpPWpGaD
Methadone—Headache—Betamethasone—psoriasis	7.47e-05	0.000354	CcSEcCtD
Methadone—Headache—Dexamethasone—psoriasis	7.47e-05	0.000354	CcSEcCtD
Methadone—Asthenia—Prednisone—psoriasis	7.45e-05	0.000353	CcSEcCtD
Methadone—HTR3A—SIDS Susceptibility Pathways—TNF—psoriasis	7.43e-05	0.0013	CbGpPWpGaD
Methadone—Pain—Methotrexate—psoriasis	7.42e-05	0.000351	CcSEcCtD
Methadone—Pruritus—Prednisone—psoriasis	7.35e-05	0.000348	CcSEcCtD
Methadone—Feeling abnormal—Methotrexate—psoriasis	7.15e-05	0.000339	CcSEcCtD
Methadone—Diarrhoea—Prednisone—psoriasis	7.1e-05	0.000336	CcSEcCtD
Methadone—Gastrointestinal pain—Methotrexate—psoriasis	7.1e-05	0.000336	CcSEcCtD
Methadone—CYP2C18—Metabolism—CYP2S1—psoriasis	7.1e-05	0.00124	CbGpPWpGaD
Methadone—Nausea—Dexamethasone—psoriasis	7.08e-05	0.000335	CcSEcCtD
Methadone—Nausea—Betamethasone—psoriasis	7.08e-05	0.000335	CcSEcCtD
Methadone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.04e-05	0.00123	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—HLA-A—psoriasis	7.01e-05	0.00123	CbGpPWpGaD
Methadone—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.93e-05	0.00121	CbGpPWpGaD
Methadone—Urticaria—Methotrexate—psoriasis	6.89e-05	0.000326	CcSEcCtD
Methadone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.89e-05	0.00121	CbGpPWpGaD
Methadone—Dizziness—Prednisone—psoriasis	6.87e-05	0.000325	CcSEcCtD
Methadone—Abdominal pain—Methotrexate—psoriasis	6.86e-05	0.000325	CcSEcCtD
Methadone—Body temperature increased—Methotrexate—psoriasis	6.86e-05	0.000325	CcSEcCtD
Methadone—OPRD1—Signaling Pathways—HCAR2—psoriasis	6.84e-05	0.0012	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CCL20—psoriasis	6.63e-05	0.00116	CbGpPWpGaD
Methadone—Vomiting—Prednisone—psoriasis	6.6e-05	0.000313	CcSEcCtD
Methadone—Rash—Prednisone—psoriasis	6.55e-05	0.00031	CcSEcCtD
Methadone—Dermatitis—Prednisone—psoriasis	6.54e-05	0.00031	CcSEcCtD
Methadone—Headache—Prednisone—psoriasis	6.5e-05	0.000308	CcSEcCtD
Methadone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.4e-05	0.00112	CbGpPWpGaD
Methadone—Hypersensitivity—Methotrexate—psoriasis	6.39e-05	0.000303	CcSEcCtD
Methadone—CYP19A1—Metabolism—NDUFA5—psoriasis	6.39e-05	0.00112	CbGpPWpGaD
Methadone—Asthenia—Methotrexate—psoriasis	6.23e-05	0.000295	CcSEcCtD
Methadone—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	6.2e-05	0.00109	CbGpPWpGaD
Methadone—Nausea—Prednisone—psoriasis	6.17e-05	0.000292	CcSEcCtD
Methadone—Pruritus—Methotrexate—psoriasis	6.14e-05	0.000291	CcSEcCtD
Methadone—OPRD1—Signaling by GPCR—CCL20—psoriasis	6.02e-05	0.00105	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—HCAR2—psoriasis	6e-05	0.00105	CbGpPWpGaD
Methadone—HTR3A—SIDS Susceptibility Pathways—IL6—psoriasis	6e-05	0.00105	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.96e-05	0.00104	CbGpPWpGaD
Methadone—Diarrhoea—Methotrexate—psoriasis	5.94e-05	0.000281	CcSEcCtD
Methadone—OPRD1—Signaling Pathways—TAGAP—psoriasis	5.93e-05	0.00104	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CCL20—psoriasis	5.81e-05	0.00102	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.75e-05	0.00101	CbGpPWpGaD
Methadone—Dizziness—Methotrexate—psoriasis	5.74e-05	0.000272	CcSEcCtD
Methadone—CYP3A7—Metabolism—NDUFA5—psoriasis	5.55e-05	0.000972	CbGpPWpGaD
Methadone—Vomiting—Methotrexate—psoriasis	5.52e-05	0.000261	CcSEcCtD
Methadone—Rash—Methotrexate—psoriasis	5.47e-05	0.000259	CcSEcCtD
Methadone—Dermatitis—Methotrexate—psoriasis	5.47e-05	0.000259	CcSEcCtD
Methadone—Headache—Methotrexate—psoriasis	5.44e-05	0.000257	CcSEcCtD
Methadone—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	5.43e-05	0.000952	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—CYP2S1—psoriasis	5.43e-05	0.000951	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCL20—psoriasis	5.28e-05	0.000924	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	5.23e-05	0.000916	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TAGAP—psoriasis	5.2e-05	0.000911	CbGpPWpGaD
Methadone—Nausea—Methotrexate—psoriasis	5.15e-05	0.000244	CcSEcCtD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	5.08e-05	0.00089	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—HCAR2—psoriasis	5.07e-05	0.000888	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.97e-05	0.000871	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CCL20—psoriasis	4.91e-05	0.00086	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.89e-05	0.000857	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.79e-05	0.000839	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—CYP2S1—psoriasis	4.72e-05	0.000826	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—IL6—psoriasis	4.69e-05	0.000822	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IFNG—psoriasis	4.68e-05	0.000819	CbGpPWpGaD
Methadone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.67e-05	0.000818	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.59e-05	0.000805	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	4.58e-05	0.000803	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCL20—psoriasis	4.46e-05	0.000781	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.44e-05	0.000778	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TAGAP—psoriasis	4.4e-05	0.00077	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.35e-05	0.000762	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.35e-05	0.000761	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.16e-05	0.000728	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—NDUFA5—psoriasis	4.1e-05	0.000719	CbGpPWpGaD
Methadone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.08e-05	0.000714	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—NDUFA5—psoriasis	4.01e-05	0.000702	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	3.88e-05	0.000679	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.72e-05	0.000652	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.72e-05	0.000652	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.65e-05	0.000638	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.58e-05	0.000627	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCL20—psoriasis	3.55e-05	0.000622	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.53e-05	0.000619	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CYP2S1—psoriasis	3.49e-05	0.000611	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—NDUFA5—psoriasis	3.47e-05	0.000608	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—CARM1—psoriasis	3.46e-05	0.000607	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CYP2S1—psoriasis	3.41e-05	0.000597	CbGpPWpGaD
Methadone—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	3.36e-05	0.000588	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.24e-05	0.000567	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CXCL8—psoriasis	3.17e-05	0.000554	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCL20—psoriasis	3.12e-05	0.000546	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—NDUFA5—psoriasis	3.1e-05	0.000543	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.08e-05	0.00054	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—TNF—psoriasis	3.03e-05	0.00053	CbGpPWpGaD
Methadone—ABCB1—Metabolism—NDUFA5—psoriasis	3.03e-05	0.00053	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.01e-05	0.000527	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CYP2S1—psoriasis	2.95e-05	0.000517	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.89e-05	0.000506	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—NDUFA5—psoriasis	2.85e-05	0.000499	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.85e-05	0.000499	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—NDUFA5—psoriasis	2.83e-05	0.000495	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.81e-05	0.000493	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CXCL8—psoriasis	2.78e-05	0.000486	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.68e-05	0.00047	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—CARM1—psoriasis	2.65e-05	0.000465	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CYP2S1—psoriasis	2.64e-05	0.000462	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.64e-05	0.000462	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCL20—psoriasis	2.63e-05	0.000461	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CYP2S1—psoriasis	2.57e-05	0.000451	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.48e-05	0.000434	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CYP2S1—psoriasis	2.42e-05	0.000425	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NDUFA5—psoriasis	2.42e-05	0.000423	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CYP2S1—psoriasis	2.4e-05	0.000421	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CXCL8—psoriasis	2.35e-05	0.000411	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—CARM1—psoriasis	2.3e-05	0.000403	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.25e-05	0.000394	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—CAT—psoriasis	2.13e-05	0.000373	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CYP2S1—psoriasis	2.05e-05	0.00036	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.99e-05	0.000349	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.96e-05	0.000343	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.92e-05	0.000336	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.87e-05	0.000327	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.86e-05	0.000327	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.79e-05	0.000313	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.74e-05	0.000305	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.72e-05	0.000301	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CARM1—psoriasis	1.7e-05	0.000298	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CARM1—psoriasis	1.67e-05	0.000292	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—APOE—psoriasis	1.66e-05	0.00029	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.64e-05	0.000287	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—CAT—psoriasis	1.63e-05	0.000286	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.62e-05	0.000285	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.59e-05	0.000278	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1.57e-05	0.000275	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.55e-05	0.000271	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.49e-05	0.000262	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.45e-05	0.000254	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—LEP—psoriasis	1.44e-05	0.000253	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—APOE—psoriasis	1.44e-05	0.000253	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PPARG—psoriasis	1.44e-05	0.000253	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CARM1—psoriasis	1.44e-05	0.000253	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.42e-05	0.00025	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—CAT—psoriasis	1.42e-05	0.000248	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.38e-05	0.000242	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.38e-05	0.000242	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.35e-05	0.000236	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.35e-05	0.000236	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.33e-05	0.000232	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.32e-05	0.000231	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CARM1—psoriasis	1.29e-05	0.000225	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—APOE—psoriasis	1.27e-05	0.000222	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—LEP—psoriasis	1.27e-05	0.000222	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—APOE—psoriasis	1.27e-05	0.000222	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.26e-05	0.000221	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CARM1—psoriasis	1.26e-05	0.00022	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.2e-05	0.000211	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.2e-05	0.000211	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CARM1—psoriasis	1.18e-05	0.000207	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.18e-05	0.000207	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CARM1—psoriasis	1.17e-05	0.000206	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PPARG—psoriasis	1.1e-05	0.000193	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TYK2—psoriasis	1.1e-05	0.000193	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—APOE—psoriasis	1.1e-05	0.000193	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.1e-05	0.000192	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.08e-05	0.000189	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—LEP—psoriasis	1.07e-05	0.000187	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—APOE—psoriasis	1.07e-05	0.000187	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CAT—psoriasis	1.05e-05	0.000184	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CAT—psoriasis	1.02e-05	0.000179	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CARM1—psoriasis	1e-05	0.000176	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NFKBIA—psoriasis	9.97e-06	0.000175	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TYK2—psoriasis	9.67e-06	0.000169	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL8—psoriasis	9.6e-06	0.000168	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PPARG—psoriasis	9.59e-06	0.000168	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.38e-06	0.000164	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL6—psoriasis	9.13e-06	0.00016	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—JUN—psoriasis	8.92e-06	0.000156	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CAT—psoriasis	8.87e-06	0.000155	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—NFKB1—psoriasis	8.59e-06	0.00015	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—psoriasis	8.42e-06	0.000147	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TYK2—psoriasis	8.17e-06	0.000143	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—APOE—psoriasis	8.14e-06	0.000143	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL6—psoriasis	8e-06	0.00014	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—APOE—psoriasis	7.96e-06	0.000139	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CAT—psoriasis	7.92e-06	0.000139	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—JUN—psoriasis	7.82e-06	0.000137	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—VEGFA—psoriasis	7.8e-06	0.000137	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CARM1—psoriasis	7.74e-06	0.000136	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CAT—psoriasis	7.73e-06	0.000135	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—STAT3—psoriasis	7.72e-06	0.000135	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NFKB1—psoriasis	7.53e-06	0.000132	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CAT—psoriasis	7.28e-06	0.000128	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CAT—psoriasis	7.22e-06	0.000126	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—psoriasis	7.11e-06	0.000125	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PPARG—psoriasis	7.09e-06	0.000124	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPARG—psoriasis	6.93e-06	0.000121	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—APOE—psoriasis	6.89e-06	0.000121	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—VEGFA—psoriasis	6.84e-06	0.00012	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—STAT3—psoriasis	6.77e-06	0.000119	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL6—psoriasis	6.76e-06	0.000118	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—JUN—psoriasis	6.61e-06	0.000116	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NFKB1—psoriasis	6.37e-06	0.000111	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CAT—psoriasis	6.17e-06	0.000108	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—APOE—psoriasis	6.15e-06	0.000108	CbGpPWpGaD
Methadone—ABCB1—Metabolism—APOE—psoriasis	6e-06	0.000105	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPARG—psoriasis	6e-06	0.000105	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TP53—psoriasis	5.89e-06	0.000103	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—VEGFA—psoriasis	5.78e-06	0.000101	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—STAT3—psoriasis	5.72e-06	0.0001	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—APOE—psoriasis	5.66e-06	9.91e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—APOE—psoriasis	5.61e-06	9.83e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL6—psoriasis	5.39e-06	9.44e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPARG—psoriasis	5.36e-06	9.39e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPARG—psoriasis	5.23e-06	9.16e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TP53—psoriasis	5.16e-06	9.05e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPARG—psoriasis	4.93e-06	8.63e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPARG—psoriasis	4.89e-06	8.56e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—APOE—psoriasis	4.79e-06	8.4e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CAT—psoriasis	4.76e-06	8.34e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL6—psoriasis	4.73e-06	8.28e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TP53—psoriasis	4.36e-06	7.65e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPARG—psoriasis	4.18e-06	7.31e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL6—psoriasis	4e-06	7e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—APOE—psoriasis	3.7e-06	6.48e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPARG—psoriasis	3.22e-06	5.64e-05	CbGpPWpGaD
